We use essential cookies to operate our site. With your consent, we may also use non-essential cookies to improve your user experience and to analyze website traffic. Click "Accept" to accept cookies and go directly to the site, click "Reject" to reject all but cookies strictly necessary for the functioning of this site. You can reset your cookie settings at any time by visiting your Bioz "my account" page and selecting the "reset cookie preferences" link.

Accept Reject

     Combing through more than 330 million products and articles...      Welcome to Your Next Discovery   
All (1)
New England Biolabs
 

1 product / 703 snippets / 40 images

98 / 100
Bioz Stars
AscI
New England Biolabs  
Catalog#: R0558
Techniques
 
Article Snippets
"ing luxCDABEF to the CBA promoter. The pCMV lux CMV promoter was excised with NheI and MluI, and a synthetic 61-bp fragment containing an AscI site (Integrated DNA Technologies) was inserted using the NEBuilder HiFi DNA Assembly Cloning Kit (HiFi; New England Biolabs). The CBA promoter was ligated into the construct using the existing NheI and newly introduced AscI sites. The SV40 promoter was exci"  (see more)
98 / 100
Bioz Stars
AscI
New England Biolabs  
star_border
Catalog#: R0558
Techniques
 
Article Snippets
"ing luxCDABEF to the CBA promoter. The pCMV lux CMV promoter was excised with NheI and MluI, and a synthetic 61-bp fragment containing an AscI site (Integrated DNA Technologies) was inserted using the NEBuilder HiFi DNA Assembly Cloning Kit (HiFi; New England Biolabs). The CBA promoter was ligated into the construct using the existing NheI and newly introduced AscI sites. The SV40 promoter was exci"  (see more)
36+  more images
a Experimental timeline and schematic of chemogenetic manipulation of the aIC in social isolation-reared mice and a schematic and representative image illustrating the selective transduction of <t>hM4Di-mCherry</t> at the injection site (highlighted in red). CNO, clozapine-N-oxide. b Immobility time of hM4Di-mCherry-expressing mice treated with 10 mg/kg ( R )-ketamine or 20 mg/kg ( S )-ketamine in the FST. Statistical analysis was performed using Levene’s test and one-way ANOVA, followed by Bonferroni’s multiple comparison test. Levene’s test: p = 0.153 (vehicle), p = 0.012 (CNO); one-way ANOVA: Vehicle, F (2, 47) = 6.198, p = 0.0041; CNO, F (2, 43) = 6.044, p = 0.0049. * p < 0.05, ** p < 0.01. c Immobility time of hM3Dq-mCherry- or mCherry-expressing mice treated with vehicle or CNO in the FST. The number in parentheses indicates the number of mice used in the experiment. Statistical analysis was performed using Levene’s test and unpaired t test. Levene’s test: p = 0.744 (mCherry), p = 0.828 (hM3Dq). * p < 0.05. Data are presented as the mean ± s.e.m.
ISOLAT
TRANSDUC
INJECT
EXP
COMP
Whole-body, gene-trap exclusive SB transposon mutagenesis results in tumor formation in <t>SB-Onc2.3</t> mice. ( a ) Comparing Sleeping Beauty transposons used in this study (T2/SB-GT and T2/Onc3) and in a similar companion study (T2/Onc2). Abbreviated allele designations for founder lines used in this work are shown to the right of each vector. ( b ) Kaplan–Meier survival plots comparing experimental and control SB-Onc2.3 cohorts (Mantel–Cox log-rank test, p < 0.0001, ). Mice in all SB-Onc2.3 cohorts with active SB mobilization developed solid tumors at multiple organ sites, however SB-Onc2.3-TG.14922 mice (orange line) had significantly decreased survival compared to the SB-Onc2.3-TG.14942 mice (purple line; Mantel–Cox log-rank test, p = 0.0015). ( c ) Kaplan–Meier survival plots comparing the relative tumor latency between various SB cohorts with whole-body mobilization by a conditionally activated from the Rosa26 - LSL SBase allele to the Rosa26 -1lox-SBase allele by whole body Beta-actin-driven Cre expression, including SB-Onc2 mice (combined data from TG.6070 and TG.6113 alleles containing an MSCV-promoter ), SB-Onc3 (data from TG.12740 allele containing a CAG-promoter ), and SB-Onc2.3 (combined data from TG.14922 and TG.14922 alleles containing no promoter) (Mantel–Cox log-rank test, p < 0.0001, ).
MUTA
PLASMID-P
EXP
( a ) Comparing Sleeping Beauty transposons used in this study (T2/SB-GT, T2/Onc3) or in a similar companion study <t>(T2/Onc2).</t> Abbreviated allele designations for founder lines used in this work are shown to the right of each vector. ( b ) Kaplan-Meier survival plots comparing experimental and control SB-Onc2.3 cohorts (Mantel-Cox log-rank test, P < 0.0001, ). Mice in all SB-Onc2.3 cohorts with active SB mobilization developed solid tumors at multiple organ sites, however SB-Onc2.3-TG.14922 mice (orange line) had significantly decreased survival compared to the SB-Onc2.3-TG.14942 mice (purple line; Mantel-Cox log-rank test, P = 0.0015). ( c ) Kaplan-Meier survival plots comparing the relative tumor latency between various SB cohorts with whole-body mobilization by a conditionally activated from the Rosa26 - LSL SBase allele to the Rosa26 -1lox-SBase allele by whole body Beta-actin-driven Cre expression, including SB-Onc2 mice (combined data from TG.6070 and TG.6113 alleles containing an MSCV-promoter ), SB-Onc3 (data from TG.12740 allele containing a CAG-promoter ), and SB-Onc2.3 (combined data from TG.14922 and TG.14922 alleles containing no promoter) (Mantel-Cox log-rank test, P < 0.0001, ).
PLASMID-P
EXP
MUTA
RECOMB
PLASMID-P
SEQ
×